Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 7707 results

  1. Lenacapavir for treating multidrug resistant HIV-1 ID6196

    Suggested remit: To appraise the clinical and cost effectiveness of lenacapavir within its marketing authorisation for treating multidrug resistant HIV-1 for wh...

    Technology appraisal guidance
    Topic selection

  2. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development [GID-TA11160] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development [GID-TA10024] Expected publication date: 28 June 2017

    Technology appraisal guidance
    In development

  6. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development [GID-TA10606] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions

    Awaiting development [GID-MT602] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  8. Ondansetron for treating alcohol-use disorder TS ID 11884

    Awaiting development [GID-TA11375] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-NG10404] Expected publication date: TBC

    NICE guideline
    In development

  11. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development [GID-TA10497] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development [GID-HTE10011] Expected publication date: TBC

    Health technology evaluations
    In development

  13. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development [GID-TA11154] Expected publication date: TBC

    Technology appraisal guidance
    In development